Skip to content

Transcranial Magnetic Stimulation in Progressive Supranuclear Palsy

Cerebellar Transcranial Magnetic Stimulation for Motor Control in Progressive Supranuclear Palsy

Status
Recruiting
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04468932
Enrollment
30
Registered
2020-07-13
Start date
2020-01-17
Completion date
2027-04-20
Last updated
2025-05-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Palsy Supranuclear, Supranuclear Palsy, Progressive

Keywords

repetitive transcranial magnetic stimulation

Brief summary

The objective of this proposal is to investigate the effect of non-invasive repetitive cerebellar transcranial magnetic stimulation (rTMS) on motor control in progressive supranuclear (PSP). The central hypothesis is that augmenting cerebellar inhibition via cerebellar rTMS will decrease postural instability in patients with PSP. We will use functional near infrared spectroscopy (fNIRS) to examine changes in motor and premotor cortical activity after cerebellar rTMS.

Interventions

DEVICERepetitive transcranial magnetic stimulation (rTMS)

Aim 1: To determine the clinical effects of rTMS targeting the cerebellum on postural instability in PSP. The hypothesis to be tested is that TMS augmentation of cerebellar inhibition will improve cerebellum-dependent balance symptoms of PSP for a period of time sufficient to improve rehabilitation outcomes. The investigators will measure a battery of objective posturography metrics and other measures of motor control, including sway and center of pressure changes to backward tilt and forward translation. Aim 2: We will use functional near infrared spectroscopy (fNIRS) to examine changes in motor and premotor cortical activity after cerebellar rTMS. The hypothesis to be tested is that premotor and motor cortical activity will decrease after cerebellar rTMS compared to sham TMS, reflecting improved cerebellar inhibition of the motor cortex after the intervention.

Sponsors

National Center of Neuromodulation for Rehabilitation
CollaboratorOTHER
Collins Medical Trust
CollaboratorOTHER
National Institutes of Health (NIH)
CollaboratorNIH
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
CollaboratorNIH
Department of Health and Human Services
CollaboratorFED
National Institute of Neurological Disorders and Stroke (NINDS)
CollaboratorNIH
National Center for Advancing Translational Sciences (NCATS)
CollaboratorNIH
Oregon Health and Science University
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
TREATMENT
Masking
TRIPLE (Subject, Caregiver, Outcomes Assessor)

Masking description

The subjects will be blinded to the order of intervention, but the PI will not be blinded in order to perform the TMS intervention. The outcome evaluators will be blinded to the intervention, however.

Intervention model description

The investigators will use a single-blind crossover design with a 4 week TMS washout period. The subjects will serve as their own controls, thus limiting confounding variables such as medication or cognitive effect.

Eligibility

Sex/Gender
ALL
Age
40 Years to 85 Years
Healthy volunteers
No

Inclusion criteria

* probable or possible PSP by the revised MDS PSP Criteria (Hoglinger 2017) * age 40-85 at time of screening * ability to understand and cooperate with simple instructions in English * ability to read at 6th grade reading level in English * ability to stand unassisted for at least 30 seconds and to be able walk independently with a walker * ability to refrain from new physical and speech therapy programs for the duration of the study * ability to remain on stable doses of any cholinergic, dopaminergic, serotonergic sedative or NMDA receptor antagonists for the duration of the study * females of child-bearing age must perform a urine pregnancy test and be on reliable birth control during the course of the study

Exclusion criteria

* other significant neurological or vestibular disorders * presence of electrically, magnetically or mechanically activated implants or history of injurious metal exposure in eyes, head, or body

Design outcomes

Primary

MeasureTime frameDescription
objective posturographyassessed on 4 days during the 8 week study periodThe primary endpoint is center of pressure shifts with tilt and with translation, and body sway in quiet stance.

Secondary

MeasureTime frameDescription
fNIRSassessed on 4 days during the 8 week study periodfunctional near infrared spectroscopy of premotor and motor areas during balance testing
speech analysisassessed on 4 days during the 8 week study periodspeech sample assessment conducted by investigator

Countries

United States

Contacts

Primary ContactGraham Harker
balance@ohsu.edu5034182601

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026